Skip to main content
SpringerLink
Log in

Clinical pharmacokinetics of disopyramide

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

Current information on the pharmacokinetics of disopyramide is reviewed with emphasis on the implications for antiarrhythmic therapy. The absolute bioavailability, the disposition half-life, the plasma clearance, and the renal clearance for normal subjects and patients are discussed. Drug-drug interactions are discussed, and a new flexible intravenous dosing schedule is proposed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. R. E. Ranney, R. R. Dean, A. Karim, and F. M. Radzialowski. Disopyramide phosphate: pharmacokinetic and pharmacologic relationships of a new antiarrhythmic agent.Arch. Int. Pharmacodyn. Ther. 191:162–188 (1971).

    CAS  PubMed  Google Scholar 

  2. K. E. Wirth, W. H. Dueball, A. Fox, and H. Michaelis. Gaschromatographische und photofluorometrische bestimmung von disopyramid in plasma und urin.Herz Kreislauf, Gesam. Ges Exp. Med. DDR 10:419–424 (1978).

    CAS  Google Scholar 

  3. R. N. Gupta, F. Eng, D. Lewis, and C. Kumana. Fluorescence photometric determination of disopyramide and mono-N-dealkylated disopyramide in plasma after separation by thin-layer chromatography.Anal. Chem. 51:455–458 (1979).

    Article  CAS  PubMed  Google Scholar 

  4. T. C. Hutsell and S. J. Stachelski. Determination of disopyramide and its mono-N-dealkylated metabolite in blood serum and urine.J. Chromatogr. 106:151–158 (1975).

    Article  CAS  PubMed  Google Scholar 

  5. A. M. J. A. Duchateau, F. W. H. M. Merkus, and F. Schobben. Rapid gas Chromatographic determination of disopyramide in serum using a nitrogen detector.J. Chromatogr. 109:432–435 (1975).

    Article  CAS  PubMed  Google Scholar 

  6. J. W. Daniel and G. Subramanian. The determination of disopyramide in blood plasma and urine.J. Int. Med. Res. 4(Suppl. 1):2–4 (1976).

    CAS  PubMed  Google Scholar 

  7. J. Vasiliades, C. Owens, and D. Pirkle. Gas-chromatographic determination of disopyramide in serum, with use of a nitrogen-selective detector.Clin. Chem. 25:311–313 (1979).

    CAS  PubMed  Google Scholar 

  8. P. J. Meffin, S. R. Harapat, and D. C. Harrison. High-pressure liquid Chromatographic analysis of drugs in biological fluids. III. Analysis of disopyramide and its mono-N-dealkylated metabolite in plasma and urine.J. Chromatogr. 132:503–510 (1977).

    Article  CAS  PubMed  Google Scholar 

  9. P. O. Lagerström and B. A. Persson. Liquid chromatography in the monitoring of plasma levels of antiarrhythmic drugs.J. Chromatogr. 149:331–340 (1978).

    Article  PubMed  Google Scholar 

  10. K. F. Ilett, L. P. Hackett, L. J. Dusci, and R. Tjokrosetio. Assay of disopyramide in plasma by high-pressure liquid chromatography.J. Chromatogr. 154:325–329 (1978).

    Article  CAS  PubMed  Google Scholar 

  11. J. J. Lima. Liquid Chromatographic analysis of disopyramide and its mono-N-dealkylated metabolite.Clin. Chem. 25:405–408 (1979).

    CAS  PubMed  Google Scholar 

  12. C. E. Pippenger. Therapeutic drug monitoring: an overview.Ther. Drug Monit. 1:3–9 (1979).

    Article  CAS  PubMed  Google Scholar 

  13. A. Karim, R. E. Ranney, and S. Kraychy. Species differences in the biotransformation of a new antiarrhythmic agent: disopyramide phosphate.J. Pharm. Sci. 61:888–893 (1972).

    Article  CAS  PubMed  Google Scholar 

  14. A. Karim, C. Cook, J. Campion, and M. Doherty. Disopyramide phosphate: tissue uptake and relationship between drug concentrations in the plasma and myocardium of rats.Arch. Int. Pharmacodyn. Ther. 228:222–236 (1977).

    CAS  PubMed  Google Scholar 

  15. A. Karim, C. Cook, and J. Campion. Placental and milk transfer of disopyramide and metabolites.Drug Metab. Dispos. 6:346–348 (1978).

    CAS  PubMed  Google Scholar 

  16. T. R. Burke, Jr., W. L. Nelson, M. Mangion, G. J. Hite, C. M. Mokier, and P. C. Ruenitz. Resolution, absolute configuration, and antiarrhythmic properties of the enantiomers of disopyramide, 4-(diisopropylamino)-2-(2-pyridyl)-2-phenylbutyramide.J. Med. Chem. 23:1044–1048 (1980).

    Article  CAS  PubMed  Google Scholar 

  17. K. M. Giacomini, J. C. Giacomini, S. E. Swezey, D. C. Harrison, W. L. Nelson, T. R. Burke, and T. G. Blaschke. The stereoselective disposition of disopyramide in the dog.J. Cardiovasc. Pharmacol. 2:825–832 (1980).

    Article  CAS  PubMed  Google Scholar 

  18. C. S. Cook, A. Karim, and P. Sollman. Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog.Drug. Metab. Dispos. 10:116–121 (1982).

    CAS  PubMed  Google Scholar 

  19. C. M. Prusa, J. H. Sanner, C. Cook, A. Karim, and P. B. Sollman. Anticholinergic activities of disopyramide isomers.Pharmacologist 22:274 (1980).

    Google Scholar 

  20. A. Karim. The pharmacokinetics of Norpace.Angiology 26:85–98 (1975).

    CAS  PubMed  Google Scholar 

  21. J. L. Cunningham, D. D. Shen, I. Shudo, and D. L. Azarnoff. The effects of urinepH and plasma protein binding on the renal clearance of disopyramide.Clin. Pharmacokin. 2:373–383 (1977).

    Article  CAS  Google Scholar 

  22. S. I. Ankier and C. M. Kaye. The influence of pH on the buccal absorption and renal excretion of disopyramide in man.Br. J. Clin. Pharmacol. 3:672–673 (1976).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. M. W. Baines, J. E. Davies, D. N. Kellett, and P. L. Munt. Some pharmacological effects of disopyramide and a metabolite.J. Int. Med. Res. 4(Suppl. 1):5–7 (1976).

    CAS  PubMed  Google Scholar 

  24. A. M. Grant, R. J. Marshall, and S. I. Ankier. Some effects of disopyramide and its N-dealkylated metabolite on isolated nerve and cardiac muscle.Eur. J. Pharmacol. 49:389–394 (1978).

    Article  CAS  PubMed  Google Scholar 

  25. J. H. Sanner, R. L. Novotney, R. H. Schulze, and P. L. Kellar. Anticholinergic properties of disopyramide phosphate and its mono-N-dealkylated metabolite. Eighth International Congress of Pharmacology, Tokyo, July 19–24, 1981. Abstr. #942, p. 506.

  26. B. Whiting, N. H. G. Holford, and L. B. Sheiner. Quantitative analysis of the disopyramide concentration-effect relationship.Br. J. Clin. Pharmacol. 9:67–75 (1980).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. M. L. Aitio and T. Vuorenmaa. Enhanced metabolism and diminished efficacy of disopyramide by enzyme induction?Br. J. Clin. Pharmacol. 9:149–152 (1980).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. M. L. Aitio. Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.Br. J. Clin. Pharmacol. 11:369–376 (1981).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. M. L. Aitio, L. Mansury, E. Tala, M. Haataja, and A. Aitio. The effect of enzyme induction on the metabolism of disopyramide in man.Br. J. Clin. Pharmacol. 11:279–285 (1981).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. S. M. Bryson, B. Whiting, and J. R. Lawrence. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.Br. J. Clin. Pharmacol. 6:409–419 (1978).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. P. H. Hinderling and E. R. Garrett. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.J. Pharmacokinet. Biopharm. 4:199–230 (1976).

    Article  CAS  PubMed  Google Scholar 

  32. J. L. Cunningham, D. D. Shen, I. Shudo, and D. L. Azarnoff. The effect of non-linear disposition kinetics on the systemic availability of disopyramide.Br. J. Clin. Pharmacol. 5:343–346 (1978).

    Article  CAS  PubMed Central  Google Scholar 

  33. A. Karim and D. L. Azarnoff. Practical problems in the assessment of drug absorption in man. InDrug Absorption. Proc. Int. Conf. Drug Absorption, Edinburgh, September 1979. ADIS Press, New York, pp. 311–323.

    Google Scholar 

  34. D. K. Dubetz, N. N. Brown, W. D. Hooper, M. J. Eadie, and J. H. Tyrer. Disopyramide pharmacokinetics and bioavailability.Br. J. Clin. Pharmacol. 6:279–281 (1978).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. J. J. Ashford, D. Carmichael, and P. H. Kidner. Pharmacokinetics of disopyramide administered by intramuscular, intravenous, and oral routes to normal volunteers.Br. J. Pharmacol. 66(Chemother. Suppl.):442–443 (1979).

    Google Scholar 

  36. A. M. J. A. Duchateau, F. W. H. M. Merkus, and R. Wilming. Biofarmaceutische en farmacokinetische aspecten van disopyramide.Pharm. Weekblad 112:145–154 (1977).

    CAS  Google Scholar 

  37. E. H. K. M. Gemmeke and M. J. S. VanThiel. Disopyramide steady-state kinetiek bij patienten met aritmieen.Pharm. Weekblad 114:533–539 (1979).

    Article  Google Scholar 

  38. K. Landmark, L. Storstein, and A. Larsen. Disopyramide plasma levels in cardiac patients on maintenance therapy.Acta Med. Scand. 206:385–389 (1979).

    Article  CAS  PubMed  Google Scholar 

  39. G. Forssell, C. Graffner, R. Nordlander, and O. Nyquist. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.Eur. J. Clin. Pharmacol. 17:209–213 (1980).

    Article  CAS  PubMed  Google Scholar 

  40. P. H. Hinderung, J. Bres, and E. R. Garrett. Protein binding and erythrocyte partitioning of disopyramide and its monodealkylated metabolite.J. Pharm. Sci. 63:1684–1690 (1974).

    Article  Google Scholar 

  41. P. J. Meffin, E. W. Robert, R. A. Winkle, S. Harapat, F. A. Peters, and D. C. Harrison. Role of concentration-dependent plasma protein binding in disopyramide disposition.J. Pharmacokin. Biopharm. 7:29–46 (1979).

    Article  CAS  Google Scholar 

  42. J. J. Lima, H. Boudoulas, and M. Blanford. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.J. Pharmacol. Exp. Ther. 219:741–747 (1981).

    CAS  PubMed  Google Scholar 

  43. A. Karim, C. Cook, R. L. Novotney, J. Zagarella, and J. Campion. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.Drug Metab. Dispos. 6:338–345 (1978).

    CAS  PubMed  Google Scholar 

  44. J. R. Lawrence, S. M. Bryson, D. J. Sumner, B. C. Campbell, and B. Whiting. The renal clearance of disopyramide after bolus intravenous injection.Biopharm. Drug Dispos. 1:51–57 (1979).

    Article  CAS  PubMed  Google Scholar 

  45. K. M. Giacomini, S. E. Swezey, K. Turner-Tamiyasu, and T. F. Blaschke. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.J. Pharmacokin. Biopharm. 10:1–13 (1982).

    Article  CAS  Google Scholar 

  46. A. P. Niarchos. Disopyramide: serum level and arrhythmia conversion.Am. Heart J. 92:57–64 (1976).

    Article  CAS  PubMed  Google Scholar 

  47. R. E. Rangno, W. Warnica, R. I. Ogilvie, J. Kreeft, and E. Bridger. Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.J. Intern. Med. Res. 4:(Suppl. 1):54–58 (1976).

    CAS  Google Scholar 

  48. J. Hulting and B. Jansson. Antiarrhythmic and electrocardiographic effects of single oral doses of disopyramide.Eur. J. Clin. Pharmacol. 11:91–99 (1977).

    Article  CAS  PubMed  Google Scholar 

  49. J. Hulting and G. Rosenhamer. Kinetics of hemodynamic and electrocardiographic changes following intravenous disopyramide.Acta Med. Scand. 205:417–423 (1979).

    Article  CAS  PubMed  Google Scholar 

  50. E. W. Robert, F. Peters, R. A. Winkle, D. C. Harrison, and P. J. Meffin. Pharmacokinetics and clinical efficacy of disopyramide phosphate.Circulation,57/58(Suppl. II): 102 (1978).

    Google Scholar 

  51. P. V. Luoma, M. L. Aitio, P. A. Kujala, and J. T. Takkunen. Intravenous disopyramide: serum levels and efficacy in supraventricular arrhythmia.Cur. Ther. Res. 27:839–843 (1980).

    Google Scholar 

  52. B. M. David, B. W. Madsen, and K. F. Ilett. Plasma binding of disopyramide.Br. J. Clin. Pharmacol. 9:614–618 (1980).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. D. B. Haughey and J. J. Lima. The influence of blood collection technique on serum and plasma protein binding of disopyramide.Eur. J. Clin. Pharmacol. 22:185–189 (1982).

    Article  CAS  PubMed  Google Scholar 

  54. E. Patterson, P. Stetson, and B. R. Lucchesi. Disopyramide plasma and myocardial tissue concentrations as they relate to antiarrhythmic activity.J. Cardiovasc. Pharmacol. 1:541–550 (1979).

    Article  CAS  PubMed  Google Scholar 

  55. E. J. Shaxted and P. J. Milton. Disopyramide in pregnancy: a case report.Curr. Med. Res. Opin. 6:70–72 (1979).

    Article  CAS  PubMed  Google Scholar 

  56. J. T. Wilson, R. D. Brown, D. R. Cherek, J. W. Dailey, B. Human, P. C. Jobe, B. R. Manno, E. J. Manno, H. M. Redetzki, and J. J. Stewart. Drug excretion in human breast milk. Principles, pharmacokinetics and projected consequences.Clin. Pharmacokin. 5:1–66 (1980).

    Article  CAS  Google Scholar 

  57. D. W. Holt, A. C. Walsh, P. V. Curry, and M. Tynan. Paediatric use of mexiletine and disopyramide.Br. Med. J. 2(6203): 1476–1477 (1979).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. W. S. Hillis, W. F. Bremner, A. Tweddel, A. R. Lorimer, and T. D. V. Lawrie. The effects of disopyramide on systolic time intervals. Proc. Disopyramide (Rythmodan) Seminar, St. John's College, Cambridge, March 24–25 (1977), p. 49.

    Google Scholar 

  59. M. Gibaldi and D. Perrier.Pharmacokinetics, Marcel Dekker, New York, 1975, p. 119.

    Google Scholar 

  60. D. A. Deano, W. Delon, R. K. Mautner, R. H. Sherman, A. E. Ehsani, and K. M. Rosen. The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.Chest 71:597–606 (1977).

    Article  CAS  PubMed  Google Scholar 

  61. J. A. Sbarbaro, D. A. Rawling, and H. A. Fozzard. Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial.Am. J. Cardiol. 44:513–520 (1979).

    Article  CAS  PubMed  Google Scholar 

  62. D. D. Shen, J. L. Cunningham, I. Shudo, and D. L. Azarnoff. Disposition kinetics of disopyramide in patients with renal insufficiency.Biopharm. Drug Dispos. 1:133–140 (1980).

    Article  CAS  PubMed  Google Scholar 

  63. B. Whiting and S. Miller. Disopyramide pharmacokinetics. Relationship to bioavailability and renal impairment. Proc. Disopyramide (Rythmodan) Seminar, St John's College, Cambridge, March 24–25 (1977), p. 11.

    Google Scholar 

  64. B. Whiting and H. L. Elliott. Disopyramide in renal impairment.Lancet 2(Dec. 24 & 31):1363 (1977).

    Article  CAS  PubMed  Google Scholar 

  65. A. Johnston, J. A. Henry, S. J. Warrington, and N. A. J. Hamer. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.Br. J. Clin. Pharmacol. 10:245–248 (1980).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  66. J. W. Ward and G. R. Kinghorn. The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.J. Int. Med. Res. 4(Suppl. 1):49–53 (1976).

    CAS  PubMed  Google Scholar 

  67. K. F. Ilett, B. W. Madsen, and J. D. Woods. Disopyramide kinetics in patients with acute myocardial infarction.Clin. Pharmacol. Ther. 26:1–7 (1979).

    CAS  PubMed  Google Scholar 

  68. K. Oksanen, A. J. Jounela, and P. J. Pentikainen. Pharmacokinetics of disopyramide in patients with acute myocardial infarction.Clin. Pharmacol. Ther. 27:276–277 (1980).

    Google Scholar 

  69. K. Landmark, J. E. Bredesen, E. Thaulow, S. Simonsen, and J. P. Amlie. Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.Eur. J. Clin. Pharmacol. 19:187–192 (1981).

    Article  CAS  PubMed  Google Scholar 

  70. G. Cramer and B. Isaksson. Quantitative determination of quinidine in plasma.Scand. J. Clin. Lab. Invest. 15:553–556 (1963).

    Article  CAS  PubMed  Google Scholar 

  71. E. Haworth and A. K. Burroughs. Disopyramide and warfarin interaction.Br. Med. J. 2:866–867 (1977).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  72. L. J. Davis, G. C. Cupit, and S. K. Shimomura. Warfarin-disopyramide interaction?Drug Intell. Clin. Pharm. 13:286 (1979).

    Google Scholar 

  73. D. Rycroft and J. W. Daniel. The excretion of D-glucaric acid in the urine of human volunteers following the administration of disopyramide.J. Int. Med. Res. 4(Suppl. 1):59–60 (1976).

    CAS  PubMed  Google Scholar 

  74. E. B. Leahey, J. A. Reiffel, E. V. Giardina, and J. T. Bigger. The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin. A prospective study.Ann. Int. Med. 92:605–608 (1980).

    Article  PubMed  Google Scholar 

  75. R. E. Small and J. H. Marshall. Quinidine-digoxin interaction. A discussion of a case report and review of the literature.Drug Intell. Clin. Pharm. 13:286–289 (1979).

    Google Scholar 

  76. E. G. Manolas, D. Hunt, and G. Sloman. Effects of quinidine and disopyramide on serum digoxin concentrations.Aust. N. Z. J. Med. 10:426–429 (1980).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research and Development Division, G. D. Searle & Co., 4901 Searle Parkway, 60077, Skokie, Illinois

    Aziz Karim, Catherine Nissen & Daniel L. Azarnoff

Authors
  1. Aziz Karim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine Nissen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel L. Azarnoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karim, A., Nissen, C. & Azarnoff, D.L. Clinical pharmacokinetics of disopyramide. Journal of Pharmacokinetics and Biopharmaceutics 10, 465–494 (1982). https://doi.org/10.1007/BF01059032

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01059032

Key words

Search

Navigation